From Reuters, March 10:
Chocolate sales are rising faster among U.S. users of GLP-1 weight-loss drugs than in the rest of the population, Swiss chocolatier Lindt & Spruengli said on Tuesday, citing data that defied forecasts the drugs would reduce confectionery demand.
The company said an internal study, based on February data from market researcher Circana, found 15% of U.S. households use GLP-1s, representing 17.5% of chocolate sales.GLP-1s include weight-loss drugs such as Novo Nordisk's Ozempic and Eli Lilly'sMounjaro.Consumers cutting back on high-calorie intake categories, such as pasta, pizza and potato chips, are still looking for some kind of indulgence, chief executive Adalbert Lechner told a news conference on Tuesday."They are upgrading to premium products. Less is more – small rewards with moment of bliss rather than mindless munching," said Lechner.Lindt, which makes chocolate Easter bunnies, said U.S. sales of premium chocolate increased among GLP-1 users by nearly 17% in 2025, compared to a 6.5% rise among non-GLP-1 users....
....MORE
And at Bakery and Snacks, March 16:
Ozempic’s chocolate contradiction: Indulgence isn’t disappearing, it’s trading up
As appetite-suppressing drugs take hold, the real shift in snacking may not be how much people eat but how deliberately they choose to indulge
There's opportunity in here, somewhere.
In the meantime, living La Vida Cocoa!
Possibly also of interest:
